Primaxin (cilastatin/imipenem)
/ Abbott
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
500
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
March 26, 2026
SHORTEN-II: Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.
(clinicaltrialsregister.eu)
- P4 | N=306 | Recruiting | Sponsor: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting
Enrollment open
March 20, 2026
SUCCESSFUL TREATMENT WITH CLOFAZIMINE FOR MACROLIDE-RESISTANT MYCOBACTERIUM ABSCESSUS INFECTION IN A PERITONEAL DIALYSIS PATIENT
(ISN-WCN 2026)
- "The patient transitioned to hemodialysis following catheter removal 11 days after symptom onset, with extensive surgical debridement and a 6-week combination antibiotic therapy including imipenem-cilastatin, amikacin and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine and sitafloxacin for 4 months...Our case represents the first successful treatment of macrolide-resistant M. abscessus PD-associated infection using clofazimine-containing combination therapy, demonstrating clofazimine as a potential therapeutic option in combination therapy. Multimodal therapy including early catheter removal, extensive surgical debridement, and prolonged multidrug antimicrobial regimens containing clofazimine may represent a viable..."
Clinical • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Infectious Disease • Nephrology • Nontuberculous Mycobacterial Disease • Polycystic Kidney Disease • Renal Disease • Respiratory Diseases • Tuberculosis • CRP
March 25, 2026
HipE Study-Hip Embolization for Pain Control in Hip Osteoarthritis and Greater Trochanteric Pain Syndrome: 12 Months Follow-Up.
(PubMed, Cardiovasc Intervent Radiol)
- "TAME is a safe and effective intervention for mild to severe OA and/or GTPS at midterm follow-up."
Journal • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology
March 06, 2026
Imipenem/cilastatin-funobactam for hospital-acquired/ventilator-associated bacterial pneumonia: a multinational phase III trial (REITAB-2)
(ESCMID Global 2026)
- No abstract available
Clinical • Late-breaking abstract • P3 data • Infectious Disease • Pneumonia • Respiratory Diseases
February 04, 2026
Oral tebipenem pivoxil tablets and intravenous imipenem-cilastatin efficacy by baseline uropathogen phenotypes and genotypes from the phase III PIVOT-PO clinical trial for complicated urinary tract infections or acute pyelonephritis
(ESCMID Global 2026)
- No abstract available
Clinical • P3 data • Infectious Disease • Nephrology
February 04, 2026
Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam compared with imipenem/cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis: integral-1, a double-blind, randomised phase III trial
(ESCMID Global 2026)
- No abstract available
Clinical • P3 data • Infectious Disease • Nephrology
February 04, 2026
Intrapulmonary pharmacokinetics of funobactam, imipenem and cilastatin in healthy subjects
(ESCMID Global 2026)
- No abstract available
Clinical • PK/PD data
March 21, 2026
FORMaT-EVOLVE: Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
(clinicaltrials.gov)
- P2 | N=300 | Not yet recruiting | Sponsor: The University of Queensland
New P2 trial • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases
March 16, 2026
Successful treatment with clofazimine for macrolide-resistant Mycobacterium abscessus infection in a peritoneal dialysis patient: A case report and literature review.
(PubMed, Perit Dial Int)
- "Initial management included early catheter removal, extensive surgical debridement, and 6 weeks of combination antibiotic therapy, including imipenem-cilastatin, amikacin, and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin, and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine, and sitafloxacin for 4 months...Based on a literature review of 67 cases of M. abscessus PD-associated infections, all six cases treated with clofazimine achieved clinical cure, but there were no reports on cases of macrolide-resistant M. abscessus treated with clofazimine. Our case represents the first successful clofazimine treatment of macrolide-resistant M. abscessus PD-associated infection, demonstrating clofazimine as a potentially effective oral antibiotic option in combination therapy,..."
Journal • Infectious Disease • Inflammation • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
March 05, 2026
Empirical antibiotic use, resistance patterns, and their impact on clinical outcomes in a Yemeni tertiary hospital.
(PubMed, New Microbes New Infect)
- "The most commonly prescribed antibiotics were Ceftriaxone, Vancomycin, Levofloxacin, Meropenem, Imipenem/Cilastatin, and Metronidazole. Significant resistance (>50%) was observed against Moxifloxacin, Clindamycin, and all tested beta-lactam agents except Cefuroxime (42%)...These findings underscore the need for effective interventions to optimize antibiotic use and mitigate the growing threat of resistance in Yemen. Strategies such as enhanced diagnostic capabilities, improved stewardship programs, and rational prescribing practices are essential to improve patient outcomes and preserve the effectiveness of antibiotics."
Clinical data • Journal
February 02, 2026
A Case of Disseminated Nocardiosis in a Heart Transplant Recipient
(ISHLT 2026)
- "He was induced with basiliximab (BAS) as a renal sparing strategy and maintained on tacrolimus, mycophenolate, and prednisone. OIP consisted of nystatin, valganciclovir, and atovaquone in lieu of TMP-SMX due to renal function...A CT chest identified nodular infiltrates concerning for disseminated infection, and empiric therapy was initiated with linezolid (LZD), imipenem-cilastatin, and TMP-SMX. TMP-SMX was later replaced with ciprofloxacin (CIP) due to AKI on CKD. The organism was subsequently identified as Nocardia pseudobrasiliensis and his antibiotic regimen was de-escalated to LZD and CIP based on susceptibilities with a planned duration of 6 months.Summary Studies have established that TMP-SMX is superior in preventing OI when compared to alternative agents such as atovaquone; furthermore, the incidence of Nocardiosis increases significantly in immunocompromised patients who are not on TMP-SMX. With implementation of the OPTN safety net program for kidney after..."
Clinical • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Respiratory Diseases • Spindle Cell Sarcoma • Transplantation
February 18, 2026
PIVOT: Pivmecillinam as oral step-down treatment for Escherichia coli febrile urinary tract infection versus standard of care; a randomized controlled non-inferiority multicenter trial
(clinicaltrialsregister.eu)
- P1/2 | N=560 | Recruiting | Sponsor: Uppsala Universitet
Head-to-Head • New P1/2 trial • Infectious Disease • Nephrology
February 07, 2026
Sheathless microcatheter: a new approach for musculoskeletal arterial embolization.
(PubMed, CVIR Endovasc)
- "This novel sheathless microcatheter approach was found to be feasible, safe, and effective without major complications within our limited sample size."
Journal • Inflammation • Musculoskeletal Diseases
February 06, 2026
Aztreonam/avibactam (Emblaveo) for complicated intra-abdominal infections.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Infectious Disease
February 06, 2026
Case Report: Rare Presentation of Nocardia cyriacigeorgica Pleural Nocardiosis in a Kidney Transplant Patient.
(PubMed, Transplant Proc)
- "This rare case of pleural nocardiosis caused by Nocardia cyriacigeorgica in a kidney transplant recipient highlights diagnostic challenges, as the presentation mimicked malignancy. High clinical suspicion is crucial when standard antimicrobial therapy fails in immunosuppressed patients. Early diagnosis through tissue culture and aggressive treatment with appropriate antibiotics, combined with immunosuppression adjustment, led to successful outcomes. This report adds valuable insights to the limited literature on this emerging pathogen in transplant recipients and emphasizes the importance of considering rare opportunistic infections in the differential diagnosis."
Journal • Chronic Kidney Disease • Cough • Infectious Disease • Nephrology • Oncology • Pulmonary Disease • Respiratory Diseases • Transplantation
January 30, 2026
Superselective transarterial embolization using imipenem/ cilastatin sodium for plantar fasciitis refractory to conservative management.
(PubMed, J Vasc Interv Radiol)
- "Superselective TAE using imipenem/ cilastatin sodium is feasible, safe, and effective in alleviating pain associated with PF refractory to conservative management, with a low risk of adverse events."
Journal • Musculoskeletal Diseases • Pain
January 31, 2026
Efficacy and safety of colistimethate sodium in treating carbapenem-resistant Gram-negative bacterial infections: an open-label, single-center, single-arm study in Chinese adults.
(ChiCTR)
- P4 | N=36 | Completed | Sponsor: Tangdu Hospital of the Fourth Military Medical University; Drug Clinical Trial Institution of Tangdu Hospital, Air Force Medical University
New P4 trial • Infectious Disease
February 03, 2026
Efficacy and side effect of transcatheter arterial embolization using a novel embolic agent for lateral epicondylitis in a diabetic patient: A case report.
(PubMed, Medicine (Baltimore))
- "This study focused on the embolic agent of TAE suggesting Smartgel MIRIP as an alternative to imipenem-cilastatin sodium without antimicrobial restriction. In addition, our report proposed DM as an important clinical history factor that can impact outcomes in TAE."
Adverse events • Journal • Diabetes • Metabolic Disorders • Musculoskeletal Pain • Pain
January 10, 2026
Investigating risk factors and antibiotic resistance of bloodstream infections causing Klebsiella pneumoniae in burn patients.
(PubMed, Medicine (Baltimore))
- "All 23 KP strains from blood cultures were 100% resistant to ciprofloxacin, cefazolin, and piperacillin/tazobactam, 75.22% resistant to amikacin, 66.32% to cefoperazone/sulbactam, 60.87% to imipenem/cilastatin, and 60.87% to meropenem, while showing low resistance to tigecycline (4.35%) and polymyxin B (0.00%). Total burn area, concurrent inhalation injury, third-degree burn area, and catheter indwelling time were significant risk factors for BSI caused by KP in patients with severe burns. KP strains were highly resistant to multiple antibiotics, necessitating careful selection of susceptible antibiotics based on their resistance profiles."
Journal • Observational data • Retrospective data • Infectious Disease • Pneumonia • Thermal Injury
January 09, 2026
Genicular Artery Embolization as a Treatment Option for Refractory Knee Pain Post Total Knee Arthroplasty: A Prospective Series.
(PubMed, Cardiovasc Intervent Radiol)
- "GAE shows efficacy as an adjunct treatment in patients with TKA and long-standing pain (> 1 year). Further research is needed to assess long-term outcomes and broader applicability."
Journal • Immunology • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Rheumatology
December 31, 2025
A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier.
(PubMed, IDCases)
- "The patient was successfully treated with a combination of imipenem/cilastatin, trimethoprim-sulfamethoxazole, and minocycline, resulting in the resolution of symptoms, and radiological and functional improvement were confirmed. It also suggests that although HTLV-1 carriers are generally considered immunocompetent, they exhibit subtle immune dysregulation that predisposes them to opportunistic infections. Therefore, clinicians should consider opportunistic infections, including those caused by Pandoraea species, in individuals without CF who have underlying structural lung disease or potential immune modulation, and utilize advanced diagnostic techniques to ensure accurate identification and appropriate treatment."
Journal • Cystic Fibrosis • Genetic Disorders • Immune Modulation • Immunology • Infectious Disease • Large Cell Carcinoma • Non‐Cystic Fibrosis Bronchiectasis • Oncology • Pulmonary Disease • Respiratory Diseases
December 29, 2025
Improving Standards for Embolization of Adhesive Capsulitis.
(PubMed, Cardiovasc Intervent Radiol)
- "Patient selection criteria, key technical aspects of arteriography and embolization, and follow-up protocols are detailed. An updated summary of the literature is presented, along with an appendix designed to facilitate standardized data collection.Level of EvidenceExpert review Level 5."
Journal • Review • Pain
December 25, 2025
The use of the ipsilateral dorsalis pedis artery approach for transarterial embolization in symptomatic chronic plantar fasciitis: a case report.
(PubMed, J Surg Case Rep)
- "A 68-year-old male (BMI 40.46 kg/m2) underwent targeted embolization of hypervascular medial plantar branches using Imipenem-Cilastatin (2 mL). The procedure was completed in under 15 minutes, with minimal blood loss and no complications. The ipsilateral Dorsalis Pedis approach enables more precise targeting and reduced radiation exposure compared with posterior tibial access, while offering fewer complications and faster recovery compared with femoral access-representing a novel and effective option."
Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Pain
December 23, 2025
Listeria monocytogenes bacteremia in an AIDS patient during pregnancy: A case report.
(PubMed, Medicine (Baltimore))
- "HIV infection during pregnancy, when complicated by L. monocytogenes bacteremia, is extremely rare; however, it carries a very high mortality rate. This case study represents one of the few documented instances of HIV infection complicated by L. monocytogenes bacteremia during pregnancy. It underscores the necessity for clinicians to enhance early detection and implement precise interventions for these rare co-infections to optimize maternal and infant outcomes."
Journal • Allergy • Human Immunodeficiency Virus • Immunology • Infectious Disease • Nephrology • Septic Shock • CRP
December 22, 2025
A case of multiple abscesses caused by Mycobacterium mageritense after salvage esophagectomy for esophageal cancer.
(PubMed, J Surg Case Rep)
- "The patient responded well to treatment with amikacin, imipenem/cilastatin, linezolid, and levofloxacin...This report highlights a rare case of a post-salvage esophagectomy patient who developed multiple abscesses due to M. mageritense. In patients with unexplained postoperative symptoms, consideration of nontuberculous mycobacterial infections may be important."
Journal • Esophageal Cancer • Infectious Disease • Nontuberculous Mycobacterial Disease • Oncology • Respiratory Diseases • CRP
1 to 25
Of
500
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20